{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:23:28Z","timestamp":1788265408688,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"DOI":"10.1093\/jac\/dkw517","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T12:07:31Z","timestamp":1478261251000},"page":"dkw517","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by<i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1093","author":[{"given":"Norihito","family":"Kaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitomo","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kosai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,12,20]]},"reference":[{"key":"2016122017351433000_dkw517v1.1","first-page":"139","article-title":"Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens","volume":"6","author":"Matsumoto","year":"2014","journal-title":"Clin Pharmacol"},{"key":"2016122017351433000_dkw517v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.02.008"},{"key":"2016122017351433000_dkw517v1.3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s10156-012-0509-1","article-title":"Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan","volume":"18","author":"Takesue","year":"2012","journal-title":"J Infect Chemother"},{"key":"2016122017351433000_dkw517v1.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1490-9"},{"key":"2016122017351433000_dkw517v1.5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04839-14"},{"key":"2016122017351433000_dkw517v1.6","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.7.2105078"},{"key":"2016122017351433000_dkw517v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2014.05.007"},{"key":"2016122017351433000_dkw517v1.8","unstructured":"Markus T Kenichiro K Annekartin R . In-vitro aerosol characterization of ME1100 inhalation solution with an eFlow handheld nebulizer and an eFlow inline nebulizer. In: Abstracts of the Fifty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2014. Abstract F-1613, p. 183. American Society for Microbiology, Washington, DC, USA."},{"key":"2016122017351433000_dkw517v1.9","unstructured":"Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard: Ninth Edition. CLSI, Wayne, PA, USA, 2012."},{"key":"2016122017351433000_dkw517v1.10","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement. M100-S24. CLSI, Wayne, PA, USA, 2014."},{"key":"2016122017351433000_dkw517v1.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00457-13"},{"key":"2016122017351433000_dkw517v1.12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijantimicag.2013.05.016","article-title":"In vivo efficacy of biapenem with ME1071, a novel metallo-\u03b2-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa","volume":"42","author":"Yamada","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2016122017351433000_dkw517v1.13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10156-011-0359-2","article-title":"In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa","volume":"18","author":"Yamada","year":"2012","journal-title":"J Infect Chemother"},{"key":"2016122017351433000_dkw517v1.14","doi-asserted-by":"publisher","DOI":"10.1159\/000048553"},{"key":"2016122017351433000_dkw517v1.15","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.24.1.4122"},{"key":"2016122017351433000_dkw517v1.16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/clinchem\/21.8.1136","article-title":"New colorimetric reaction for end-point, continuous-flow, and kinetic measurement of urea","volume":"21","author":"Jung","year":"1975","journal-title":"Clin Chem"},{"key":"2016122017351433000_dkw517v1.17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00277-11"},{"key":"2016122017351433000_dkw517v1.18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0166"},{"key":"2016122017351433000_dkw517v1.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"2016122017351433000_dkw517v1.20","doi-asserted-by":"crossref","unstructured":"Paul M Lador A Grozinsky-Glasberg S . Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014 ; issue 1: CD003344.","DOI":"10.1002\/14651858.CD003344.pub3"},{"key":"2016122017351433000_dkw517v1.21","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201311-395FR"},{"key":"2016122017351433000_dkw517v1.22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00480-05"},{"key":"2016122017351433000_dkw517v1.23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00133-06"},{"key":"2016122017351433000_dkw517v1.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-011-2420-0"},{"key":"2016122017351433000_dkw517v1.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201011-1894OC"},{"key":"2016122017351433000_dkw517v1.26","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2013.1100"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/4\/1123\/11021549\/dkw517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T03:59:30Z","timestamp":1601179170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,20]]},"references-count":26,"alternative-id":["10.1093\/jac\/dkw517"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw517","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,20]]}}}